Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Adverse Events Following Immunization (AEFI) With Alternate Schedules of COVID-19 Vaccines in Canada: is "Mix and Match" of the Second Dose (MOSAIC-1;CT24a) and Additional Doses (MOSAIC-2 and MOSAIC-3;CT24b and CT24c) Safe and Immunogenic?

NCT04894435 is registered in ClinicalTrials.gov with Canadian Immunization Research Network as lead sponsor.

NCT NCT04894435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04894435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Adverse Events Following Immunization (AEFI) With Alternate Schedules of COVID-19 Vaccines in Canada: is "Mix and Match" of the Second Dose (MOSAIC-1;CT24a) and Additional Doses (MOSAIC-2 and MOSAIC-3;CT24b and CT24c) Safe and Immunogenic?
Lead sponsor
Canadian Immunization Research Network
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 20, 2021
Completion date
August 1, 2025
Enrollment
669 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19